FMI, Matrix Group release animated video as part of association’s ‘Supermarket Facts Video Series’
ARLINGTON, Va. — Food Marketing Institute and Matrix Group, a digital agency specializing in e-marketing, on Thursday announced the release of a new animated video as part of the trade association’s "Supermarket Facts Video Series."
With two-thirds of American shoppers believing that their food choices are an important factor affecting their health, supermarkets are hiring an increasing number of registered dietitians to help them make healthy decisions.
Using infographics and animation, this video illustrates how supermarkets are supporting their health and wellness strategies.
No comments found
IMS opens IPO at $20 per share
DANBURY, Conn. — IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 9.75 million shares of common stock at the public offering price, less underwriting discounts and commissions.
IMS Health expects to use substantially all of the net proceeds from the shares offered by it to repay existing long-term debt. IMS Health will not receive any of the proceeds from the sale of shares by the selling shareholders.
The offering is expected to close on April 9, 2014, subject to customary closing conditions. The shares are expected to begin trading on the New York Stock Exchange on April 4, 2014 under the ticker symbol “IMS.”
No comments found
NABP advises pharmacies not to dispense combination drugs with more than 325 mg of APAP per dose
MOUNT PROSPECT, Ill. — The National Association of Boards of Pharmacy on Wednesday recommended that pharmacies no longer dispense combination drugs containing more than 325 mg of acetaminophen per dosage unit in light of recent regulatory action.
NABP also advises that pharmacists consult with prescribers to discuss alternative products with lower acetaminophen doses.
The Food and Drug Administration is withdrawing approval of 108 abbreviated new drug applications for prescription combination drug products containing more than 325 mg of acetaminophen per dosage unit. For the 108 ANDAs, the manufacturers asked to withdraw their applications, as announced in the March 27, 2014 Federal Register notice. A second Federal Register notice addresses the applications of six manufacturers who have discontinued marketing their products, but who have not withdrawn their applications.
The notice also announces FDA’s intention to begin the process of withdrawing approval of those applications.
FDA asked manufacturers to voluntarily withdraw these products from the market to reduce the risk of severe liver injury from inadvertent acetaminophen overdose. In January 2014, FDA recommended that providers consider prescribing acetaminophen products containing 325 mg or less per dose.
Quoting an FDA report, acetaminophen's narrow safety margin places a large fraction of users close to a toxic dose in the ordinary course of use. Taken over several days, as little as 25 percent above the maximum daily dose – or just two additional extra strength pills a day – has been reported to cause liver damage, according to the agency. http://www.propublica.org/article/tylenol-mcneil-fda-use-only-as-directed
The list of risks for acetaminophen is long and growing. The most serious concerns are two new studies which show adverse neurodevelopment in children whose mothers used acetaminophen while they were pregnant. The study in 3 year olds (Brandlistuen et al. 2013) found a 70% increased risk of motor and behavioral problems and double the risk of communication problems (autism phenotypes). The study in 7 year olds (Liew et al. 2014) found increased risk of ADHD behaviors and Hyperkinetic Disorders. This is in addition to close to 30 studies finding an association to asthma and allergic disorders, 4 studies finding an association to male congenital malformations (cryptorchidism) and additional studies finding associations to skin disorders and mind numbing (relief of existential dread).